Sengenics Merger with Standard BioTools Amplifies Proteomics Reach

Summa Equity, a private equity firm, has orchestrated the merger of Sengenics, a leader in functional proteomics, with Standard BioTools, a pioneer in advancing drug development through unique biological insights. Sengenics, leveraging its proprietary KREX TM protein-folding technology, enhances Standard BioTools' offerings which focus on improving patient care and advancing oncology and immunology research. This strategic merger aims to broaden the reach and capabilities in the proteomics industry through the integration of precise antibody profiling techniques, expanding Standard BioTools' ability to empower pharmaceutical companies and research institutions in the pursuit of novel disease insights and accelerated biomarker discovery.